From the American Academy of Ophthalmology

This analysis of data from two randomized clinical trials included 1,048 patients with diabetic macular edema (DME) treated with either 1 of the 2 dexamethasone dosages or sham treatment and followed for up to 39 months. More patients in the 0.7 mg implant group experienced a ≥15-letter improvement in BCVA (22.2% vs.18.4% in the 0.35 mg implant, and 12% of controls). Additionally, mean average reduction in central retinal thickness was greater in the implant groups (−111.6 μm and −107.9 μm) than in the sham group (−41.9 μm). However, rates of cataract-related adverse events in phakic eyes were 67.9%, 64.1%, and 20.4% in the 0.7 mg implant, 0.35 mg implant, and sham group, respectively. Ophthalmology, October 2014